Determination of nomifensine by a sensitive radioimmunoassay. 1977

W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann

1. A radioimmunoassay (RIA) has been developed for determination of both nomifensine and total nomifensine (nomifensine + conjugated nomifensine) in serum, plasma, and urine. 2. Antibodies were prepared in rabbits by immunization with N-(8-Nomifensine) succinamic acid-bovine serum albumin. 3H-labelled drug was used as tracer. Separation of free from antibody-bound nomifensine was carried out using dextran-coated charcoal. For determination of total nomifensine, the acid-labile conjugate was split by acidification. 3. The limit of detection for nomifensine is 300 pg/ml plasma and the cross-reactivity of the metabolites is less that 1%. The influence of conjugated nomifensine on the results of nomifensine can be corrected. 4. Pharmacokinetics of nomifensine were determined in healthy volunteers after oral administration of 100 mg 14C-labelled drug. Peak levels of 14C radioactivity (2,150 ng/ml), total nomifensine (1,252 ng/ml) and nomifensine (53 ng/ml) appeared within 1.5-2 h; the half-life of elimination from plasma was 1.5-2 hours. The advantages of this routine method are high sensitivity, the requirement of small amounts of plasma, and simple handling.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D009627 Nomifensine An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266) Hoe-984,Linamiphen,Merital,Nomifensin,Nomifensine Maleate,Nomifensine Maleate (1:1),Hoe 984,Hoe984,Maleate, Nomifensine
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
November 1981, British journal of clinical pharmacology,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
December 1976, Scandinavian journal of clinical and laboratory investigation,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
June 1984, Radioisotopes,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
August 1985, Journal of pharmacobio-dynamics,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
November 1973, Lancet (London, England),
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
September 1977, Obstetrical & gynecological survey,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
September 1995, Annals of clinical biochemistry,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
January 1980, Problemy endokrinologii,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
November 1988, Arzneimittel-Forschung,
W Heptner, and M J Badian, and S Baudner, and O E Christ, and H M Fraser, and W Rupp, and K E Weimer, and H Wissmann
January 1983, Gynecologic and obstetric investigation,
Copied contents to your clipboard!